Boston Scientific updates post-procedural care options for atrial appendage closure device
New England Council member Boston Scientific Corporation received FDA approval to expand instructions on the WATCHMAN FLX Left Atrial Appendage Closure device which now provides doctors with another tool to prevent blood clots after the device is inserted.
With this new expansion, doctors now have an alternative treatment option for patients with non-valvular atrial fibrillation. Now, doctors can use the device along with a 45-day dual antiplatelet therapy as opposed to a 45-day oral anticoagulation and aspirin post-procedural treatment. In Europe, this labeling to include both post-procedural drugs have been in place since 2017. This new expansion will give doctors more freedom to determine the best treatment option for each individual patient.
Dr. Ian Meredith, global chief medical officer at Boston Scientific, said, “this revised labeling provides physicians more flexibility to exercise their clinical judgment based on individual patient characteristics to determine the most appropriate post-procedural antithrombotic medication regimen.”
The New England Council work like to congratulate Boston Scientific on its commitment to developing life-changing technologies.